Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more
Guangdong Taienkang Pharmaceutical Co. Ltd (301263) - Total Liabilities
Latest total liabilities as of June 2025: CN¥690.44 Million CNY
Based on the latest financial reports, Guangdong Taienkang Pharmaceutical Co. Ltd (301263) has total liabilities worth CN¥690.44 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangdong Taienkang Pharmaceutical Co. Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Guangdong Taienkang Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guangdong Taienkang Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Guangdong Taienkang Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Also Holding AG
SW:ALSN
|
Switzerland | CHF3.29 Billion |
|
Fielmann AG
LSE:0MG1
|
UK | €923.97 Million |
|
Premier Financial Corp
NASDAQ:PFC
|
USA | $7.58 Billion |
|
ArcSoft Corp Ltd
SHG:688088
|
China | CN¥364.94 Million |
|
OceanFirst Financial Corp
NASDAQ:OCFC
|
USA | $12.90 Billion |
|
BNP Paribas Bank Polska S.A.
WAR:BNP
|
Poland | zł151.96 Billion |
|
Bringspring Science and Tech
SHE:300290
|
China | CN¥542.92 Million |
|
United Renewable Energy Co Ltd
TW:3576
|
Taiwan | NT$14.17 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Guangdong Taienkang Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangdong Taienkang Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangdong Taienkang Pharmaceutical Co. Ltd (2019–2024)
The table below shows the annual total liabilities of Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥494.67 Million | +23.75% |
| 2023-12-31 | CN¥399.72 Million | +115.33% |
| 2022-12-31 | CN¥185.63 Million | -19.89% |
| 2021-12-31 | CN¥231.71 Million | -5.47% |
| 2020-12-31 | CN¥245.12 Million | +35.31% |
| 2019-12-31 | CN¥181.16 Million | -- |